243 related articles for article (PubMed ID: 35116520)
21. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
Robak T; Witkowska M; Smolewski P
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
[TBL] [Abstract][Full Text] [Related]
22. Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.
Du S; Bota D; Kong XT
Neurol Int; 2022 Jun; 14(3):574-580. PubMed ID: 35893281
[TBL] [Abstract][Full Text] [Related]
23. Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.
Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
Anticancer Res; 2022 Aug; 42(8):4173-4178. PubMed ID: 35896257
[TBL] [Abstract][Full Text] [Related]
24. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
25. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Muqbil I; Chaker M; Aboukameel A; Mohammad RM; Azmi AS; Ramchandren R
Heliyon; 2019 Aug; 5(8):e02290. PubMed ID: 31508518
[TBL] [Abstract][Full Text] [Related]
26. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib brain distribution: a preclinical study.
Goldwirt L; Beccaria K; Ple A; Sauvageon H; Mourah S
Cancer Chemother Pharmacol; 2018 Apr; 81(4):783-789. PubMed ID: 29476222
[TBL] [Abstract][Full Text] [Related]
28. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
29. Lymphomas of Central Nervous System.
Yokogami K; Azuma M; Takeshima H; Hirai T
Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.
Lu J; Do B; Primeaux B
J Oncol Pharm Pract; 2024 Feb; ():10781552241232331. PubMed ID: 38356268
[TBL] [Abstract][Full Text] [Related]
31. Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.
Cheng Q; Wang J; Lv C; Xu J
Onco Targets Ther; 2021; 14():3367-3372. PubMed ID: 34079282
[TBL] [Abstract][Full Text] [Related]
32. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract][Full Text] [Related]
33. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
34. The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS.
Xia M; Liu YN; Chen J; Xu RA; Dai G
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38213178
[TBL] [Abstract][Full Text] [Related]
35. Update on Novel Therapeutics for Primary CNS Lymphoma.
Schaff LR; Grommes C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771535
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib in B-cell lymphoma: single fighter might be enough?
Xue C; Wang X; Zhang L; Qu Q; Zhang Q; Jiang Y
Cancer Cell Int; 2020; 20():467. PubMed ID: 33005100
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
38. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
39. Targets and treatments in primary CNS lymphoma.
von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
[TBL] [Abstract][Full Text] [Related]
40. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
Front Immunol; 2019; 10():2129. PubMed ID: 31552054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]